Skip to main content
. 2016 Mar 1;22(3):212–222. doi: 10.1089/acm.2015.0214

Table 1.

Comparison of Baseline Demographic and Disease-Related Characteristics by Group (n = 84)

Characteristic Western medicine (n = 54) Combined treatment (n = 30) p-Value
Mean age ± SD (yr) 61.33 ± 11.12 58.31 ± 10.79 0.236a
Sex
 Male 35 (64.8) 22 (73.3) 0.423
 Female 19 (35.2) 8 (26.7)  
Marital status
 Single 2 (3.7) 2 (6.7) 0.742b
 Married 48 (88.9) 24 (80.0)  
 Divorced 1 (1.9) 1 (3.3)  
 Widow/widower 3 (5.6) 3 (10.0)  
Education
 Junior high 39 (72.2) 14 (46.7) 0.055
 High school 10 (18.5) 9 (30.0)  
 College 5 (9.3) 7 (23.3)  
Employed
 No 39 (72.2) 19 (63.3) 0.550
 Yes 15 (27.8) 11 (36.7)  
Economic status
 Insufficient 22 (40.7) 8 (26.7) 0.189b
 Moderate 27 (50.0) 20 (66.7)  
 Sufficient 5 (9.3) 2 (6.7)  
Comorbidity
 No 23 (42.6) 15 (50.0) 0.671
 Yesc 31 (57.4) 15 (50.0)  
Lung cancer type
 Adenocarcinoma 42 (80.8) 18 (60.0) 0.214b
 Large-cell carcinoma 1 (1.9) 0 (0.0)  
 Squamous-cell carcinoma 8 (15.4) 10 (33.3)  
 Non–small-cell carcinoma 1 (1.9) 2(6.7)  
 Missing 2 0  
Stage of cancer
 IIIA 3 (5.7) 4 (13.3) 0.206b
 IIIB 12 (22.6) 10 (33.3)  
 IV 38 (71.7) 16 (53.3)  
 Missing 1 0  
Western therapy
 Chemotherapy 27 (50.9) 18 (60.0) 0.690b
 Chemotherapy + radiation therapy 12 (22.6) 7 (23.3)  
 Targeted therapy 8 (15.1) 4 (13.3)  
 Chemotherapy + targeted therapy 3 (5.7) 0 (0.0)  
 Targeted therapy + radiation therapy 3 (5.7) 1 (3.3)  
 Missing 1 0  
Chemotherapy
 Docetaxel + cisplatin 16 (43.2) 15 (60.0) 0.09b
 Gemcitabine 2 (5.4) 2 (8.0)  
 Pemetrexed disodium + cisplatin 7 (18.9) 2 (8.0)  
 Oral vinorelbine + cisplatin 4 (10.8) 3 (12.0)  
 Docetaxel 8 (21.) 0 (0.0)  
 Gemcitabine + cisplatin 0 (0.0) 3 (12.0)  
 Missing 5 0  

Unless otherwise noted, values are number (percentage).

a

Independent t-test.

b

Fisher exact test.

c

Comorbidities include hypertension and diabetes mellitus.

SD, standard deviation.